"Cancer Vaccines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
| Descriptor ID |
D019496
|
| MeSH Number(s) |
D20.215.894.200
|
| Concept/Terms |
Cancer Vaccines- Cancer Vaccines
- Vaccines, Tumor
- Vaccines, Neoplasm
- Tumor Vaccines
- Vaccines, Cancer
- Neoplasm Vaccines
|
Below are MeSH descriptors whose meaning is more general than "Cancer Vaccines".
Below are MeSH descriptors whose meaning is more specific than "Cancer Vaccines".
This graph shows the total number of publications written about "Cancer Vaccines" by people in this website by year, and whether "Cancer Vaccines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 3 | 0 | 3 |
| 2002 | 2 | 1 | 3 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 2 | 1 | 3 |
| 2008 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 7 | 1 | 8 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 3 | 7 |
| 2014 | 6 | 1 | 7 |
| 2015 | 0 | 3 | 3 |
| 2016 | 3 | 1 | 4 |
| 2017 | 0 | 3 | 3 |
| 2019 | 4 | 0 | 4 |
| 2020 | 4 | 2 | 6 |
| 2021 | 2 | 1 | 3 |
| 2022 | 2 | 0 | 2 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cancer Vaccines" by people in Profiles.
-
Terai M, Sato T. Individualised neoantigen cancer vaccine therapy. Lancet. 2024 02 17; 403(10427):590-591.
-
Andrews CE, Zilberberg J, Perez-Olle R, Exley MA, Andrews DW. Targeted immunotherapy for glioblastoma involving whole tumor-derived autologous cells in the upfront setting after craniotomy. J Neurooncol. 2023 Dec; 165(3):389-398.
-
Muller AJ, Thomas S, Prendergast GC. A Brief Overview of Cancer Vaccines. Cancer J. 2023 Jan-Feb 01; 29(1):34-37.
-
Flickinger JC, Singh J, Yarman Y, Carlson RD, Barton JR, Waldman SA, Snook AE. T-Cell Responses to Immunodominant Listeria Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C. Front Immunol. 2022; 13:855759.
-
Hewitt DB, Nissen N, Hatoum H, Musher B, Seng J, Coveler AL, Al-Rajabi R, Yeo CJ, Leiby B, Banks J, Balducci L, Vaccaro G, LoConte N, George TJ, Brenner W, Elquza E, Vahanian N, Rossi G, Kennedy E, Link C, Lavu H. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. Ann Surg. 2022 01 01; 275(1):45-53.
-
Kottke T, Tonne J, Evgin L, Driscoll CB, van Vloten J, Jennings VA, Huff AL, Zell B, Thompson JM, Wongthida P, Pulido J, Schuelke MR, Samson A, Selby P, Ilett E, McNiven M, Roberts LR, Borad MJ, Pandha H, Harrington K, Melcher A, Vile RG. Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy. Nat Commun. 2021 03 26; 12(1):1930.
-
Bashir B, Flickinger JC, Snook AE. Vaccines and immune checkpoint inhibitors: a promising combination strategy in gastrointestinal cancers. Immunotherapy. 2021 05; 13(7):561-564.
-
Melssen MM, Pollack KE, Meneveau MO, Smolkin ME, Pinczewski J, Koeppel AF, Turner SD, Sol-Church K, Hickman A, Deacon DH, Petroni GR, Slingluff CL. Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials. Cancer Immunol Immunother. 2021 Aug; 70(8):2151-2164.
-
Savoy M. What's New in Vaccine Science. Prim Care. 2020 Sep; 47(3):517-528.
-
Carlson RD, Flickinger JC, Snook AE. Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy. Toxins (Basel). 2020 04 09; 12(4).